"Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2" by Filip Van den Bosch

Article

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2

RMD Open (2018)

Filip Van den Bosch, Ghent University Hospital
Philip J Mease, University of Washington
Joachim Sieper, Charité
Dominique L Baeten, Academic Medical Center
Yinglin Xia
Su Chen
Aileen L Pangan, Charité
In-Ho Song, Charité

Link

Disciplines

Physical Therapy and
Medicine and Health Sciences

Publication Date

February 1, 2018

DOI

10.1136/rmdopen-2017-000566

Citation Information

Filip Van den Bosch, Philip J Mease, Joachim Sieper, Dominique L Baeten, et al.. "Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2" RMD Open Vol. 4 Iss. 1 (2018)
Available at: http://works.bepress.com/philip-mease/20/